Table 3 The initially applied empirical antimicrobial therapies
|  | Total (n = 61) | ITV group (n = 38) | ITV + ITC group (n = 23) | P |
|---|---|---|---|---|
Before infection (n, %) | Â | Â | Â | 0.684 |
M/I + vancomycin | 23, 37.70% | 15, 39.47% | 8, 34.78% |  |
M/I + linezolid | 9, 14.75% | 7, 18.42% | 2, 8.70% |  |
M/I + cefperazone-sulbactam | 2, 3.28% | 2, 5.26% | 0, 0.00% |  |
M/I | 11, 18.03% | 7, 18.42% | 4, 17.39% | Â |
Tigecycline + cefperazone-sulbactam | 10, 16.39% | 6, 15.78% | 4, 17.39% | Â |
Tigecycline | 2, 3.28% | 1, 2.63% | 1, 4.34% | Â |
Ceftriaxone | 4, 6.56% | 4, 10.53% | 0, 0.00% | Â |
Cefperazone-sulbactam + vancomycin | 1, 1.64% | 1, 2.63% | 0, 0.00% | Â |
Cefperazone-sulbactam | 3, 4.92% | 3, 7.89% | 3, 13.04% | Â |
Piperacillin-tazobactam | 6, 9.84% | 6, 15.79% | 7, 30.43% | Â |
After infection (n, %) | Â | Â | Â | 0.723 |
M/I + amikacin | 3, 4.92% | 3, 7.89% | 0, 0.00% |  |
M/I + tigecycline | 12, 19.67% | 8, 21.05% | 4, 17.39% |  |
M/I + cefperazone-sulbactam | 7, 11.48% | 4, 10.52% | 3, 13.04% |  |
M/I | 11, 18.03% | 8, 21.05% | 3, 13.04% | Â |
Tigecycline+cefperazone-sulbactam | 19, 31.15% | 10, 6.32% | 9, 39.13% | Â |
Cefperazone-sulbactam | 8, 13.11% | 4, 10.53% | 4, 17.39% | Â |
Cefperazone-sulbactam + amikacin | 1, 1.64% | 1, 2.63% | 0, 0.00% | Â |